Literature DB >> 10480442

Potential role of the microvasculature in progression of heart failure.

P P Liu1, S Mak, D J Stewart.   

Abstract

After cardiac injury, there are changes in the cardiac myocyte morphology, function, matrix, and molecular gene expression. These all play an important role in remodeling of the injured heart, contributing to the progression toward heart failure. The role of the microvasculature in the progression toward heart failure is less well characterized. However, laboratory studies have established that there are important interactions between the microvascular endothelium and the myocyte. Furthermore, in a multitude of animal models of heart failure and cardiomyopathy, there is always an association with microvascular abnormalities. Reversal of these abnormalities is also associated with improvement in the cardiomyopathy. Major mediators that likely play an important role in the microvasculature include endothelin and nitric oxide. These are elaborated by both endothelium and myocyte compartments of the myocardium. Preliminary clinical studies already demonstrate that microvascular ischemia may have prognostic power in patients with nonischemic dilated cardiomyopathy. Results from these studies showed a reduction in mortality from treatment with amlodipine, suggesting a possible benefit based on changes in the microvasculature.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10480442     DOI: 10.1016/s0002-9149(99)00361-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Identification of a specific pattern of downregulation in expression of isoforms of vascular endothelial growth factor in dilated cardiomyopathy.

Authors:  R A De Boer; R H Henning; R A Tio; Y M Pinto; R M H J Brouwer; R J Ploeg; M Böhm; W H Van Gilst; D J Van Veldhuisen
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

2.  Identification of a restriction point at the M/G1 transition in CHO cells.

Authors:  E Hullemann; J J M Bijvelt; A J Verkleij; C T Verrips; J Boonstra
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

Review 3.  Regeneration of the vascular compartment.

Authors:  M U Becher; G Nickenig; N Werner
Journal:  Herz       Date:  2010-08       Impact factor: 1.443

4.  Simvastatin preserves cardiac function in genetically determined cardiomyopathy.

Authors:  Seena S Abraham; Juan C Osorio; Shunichi Homma; Jie Wang; Harshwardhan M Thaker; James K Liao; Seema Mital
Journal:  J Cardiovasc Pharmacol       Date:  2004-03       Impact factor: 3.105

Review 5.  Vascular dysfunction in idiopathic dilated cardiomyopathy.

Authors:  Santiago Roura; Antoni Bayes-Genis
Journal:  Nat Rev Cardiol       Date:  2009-07-28       Impact factor: 32.419

6.  Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor.

Authors:  Juan C Osorio; Faisal H Cheema; Timothy P Martens; Naila Mahmut; Caroline Kinnear; Ana M D Gonzalez; William Bonney; Shunichi Homma; James K Liao; Seema Mital
Journal:  Can J Physiol Pharmacol       Date:  2008-09       Impact factor: 2.273

7.  Ocular Alterations Associated with Primary Congenital Heart Disease - A Cross-sectional Study.

Authors:  Manuel A P Vilela; Carina G Colossi; Henrique P Freitas; Giulia Del Valle; Lúcia C Pellanda
Journal:  Middle East Afr J Ophthalmol       Date:  2020-04-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.